Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- ASKA Sets Up Office in London
April 2, 2021
- Takeda Wraps Up Divestment of European OTC Biz
April 2, 2021
- Takeda Completes Divestment of 4 Diabetes Meds to Teijin in Japan
April 2, 2021
- Mitsubishi Tanabe Wins US Patent Suit on Canagliflozin
April 2, 2021
- Viatris, Astellas to Wind Up Lipitor Copromotion at July-End
April 2, 2021
- Sandoz Shooting for Top Foreign Player in Japan Generic Market by 2023
April 1, 2021
- Fujifilm Holdings Names Teiichi Goto New President
April 1, 2021
- Eisai Snags Rights to Vibegron in 4 ASEAN States
April 1, 2021
- Takeda Completes Divestment of Consumer Healthcare Unit to Blackstone
April 1, 2021
- Eisai/MSD File Lenvima-Keytruda Pair in Japan, Seeking 1st Nod for RCC
April 1, 2021
- Opdivo Filed as Adjuvant for Resected Urothelial Cancer in Japan
April 1, 2021
- Daiichi Sankyo to Terminates Vaccine Business Alliance with Sanofi in Japan
April 1, 2021
- Rohto to Invest in Kobe University Spin-Off to Develop Bio-Foundry
April 1, 2021
- GHIT Fund to Invest 2.3 Billion Yen in 10 Projects for Malaria, TB, Tropical Diseases
April 1, 2021
- Fujifilm Reorganizes Healthcare Biz Focusing on Biologics CDMO, Drug Development Support
April 1, 2021
- Astellas Integrates Audentes, Sets Up New In-House Unit for Gene Therapy
April 1, 2021
- Celgene Files Its 2nd CAR-T Therapy Ide-Cel in Japan: BMS
April 1, 2021
- Japan Trials Get Underway for AstraZeneca’s COVID-19 Antibody Therapy
April 1, 2021
- Lenvima/Keytruda Combo Accepted for EU Review for RCC, Endometrial Cancer
March 31, 2021
- Sumitovant Gets Entire Stake in Urovant: Sumitomo Dainippon
March 31, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…